{"id":"W4200579141","doi":"10.1007/s40273-021-01106-6","title":"Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne; Hôpital Notre-Dame; Centre intégré de santé et de services sociaux de Chaudière-Appalaches","funders":"Sanofi Genzyme; EMD Serono; Monash University; Novartis Pharma; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Mylan; Biogen; MedDay Pharmaceuticals; Celgene; Sanofi","keywords":"Fingolimod; Natalizumab; Medicine; Multiple sclerosis; Health economics; Relapsing remitting; Cost effectiveness; Quality of Life Research; Public health; Pharmacoeconomics; Disease; Intensive care medicine; Physical therapy; Immunology; Internal medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002077218,0.0002211624,0.0006069823,0.0004781826,0.00009129757,0.00004291809,0.0001024062,0.00004106896,0.00000239265],"category_scores_gemma":[0.0009491281,0.0001777109,0.00003132331,0.0006185203,0.0001770542,0.0001753977,0.0001787483,0.0003332572,5.745998e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003524288,"about_ca_system_score_gemma":0.0001180491,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007255175,"about_ca_topic_score_gemma":0.0003161863,"domain_scores_codex":[0.996995,0.00171355,0.0003488867,0.0004398438,0.0001730214,0.0003297151],"domain_scores_gemma":[0.9943333,0.005105529,0.00010129,0.0002005752,0.0001425402,0.000116716],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02873248,0.0004002667,0.9441116,0.0005008257,0.0001019488,0.000020663,0.005756407,0.003408527,0.01413404,0.00001924375,0.000001801703,0.002812229],"study_design_scores_gemma":[0.01839779,0.0001760934,0.9660982,0.00184798,0.00002659233,0.000001660896,0.00100555,0.007077301,0.005152516,0.00001270541,0.00003168635,0.0001718972],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970742,0.0003568262,0.00004157308,0.0002519584,0.00003140032,0.002165669,0.00005847053,0.00000966577,0.00001026415],"genre_scores_gemma":[0.9991381,0.000175621,0.0001632346,0.0001267385,0.000008989567,0.0003351349,0.00002866081,0.00002287095,6.616314e-7],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02198666,"threshold_uncertainty_score":0.724684,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1193435317011464,"score_gpt":0.3735801482993999,"score_spread":0.2542366165982535,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}